Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused
negativeNegative
AI Analysis
Summary
Novartis halted its CD19-directed CAR-T trials following three patient deaths caused by a dangerous immune system response, and Bristol Myers Squibb has also paused its similar CAR-T program for safety review.
Clinical Trial Data
Outcome Details
Three patient deaths in Novartis CAR-T trials due to dangerous immune system response; both Novartis and Bristol Myers Squibb programs placed on hold for safety review
Importance:9/10
Sentiment:
-0.95
CAR-Tsafetytrial haltadverse eventsimmunotherapydeaths
Read the original article
Published by Endpoints News on September 1, 2026 12:01 AM